Merck & Co., Inc.’s new treatment for pulmonary arterial disease, Winrevair, is launching at a time when the burden of patient cost sharing in Medicare Part D is easing considerably, removing a significant potential barrier to access.
Key Takeaways
-
Medicare Part D expected to be important market for Winrevair.
Winrevair (sotatercept) is a first-in-class activin signaling inhibitor for PAH, a rare, progressive disease that affects approximately 40,000 people in...







